Khaled Shawwa is a Nephrology physician. OpenAlex indexes 66 publications with 836 citations (h-index 15); ClinicalTrials.gov lists 1 registered study matched to this name.
Overview
Scholarship
indexed output and impact (OpenAlex)Distinct works indexed by OpenAlex, matched via ORCID.
Total citations across indexed works.
Hirsch index, productivity × impact (OpenAlex).
Clinical & industry
trials, payments and federal fundingContact
The practice address and phone this provider lists in the federal NPPES (CMS) registry.
Practice address
200 1st St SW
Mayo Clinic
Rochester, MN 55905
Telephone
507-284-2511Provider last certified this registry record 15 Apr 2022.
Clinical trials
- Discontinuing CRRT in Patients with Acute Kidney Injury
Sponsor: West Virginia University
Registered studies on ClinicalTrials.gov where the overall official or a site investigator name-matches this physician, confirmed against known institution/geography. Latest few shown; the full list is part of the full profile.
Industry payments
3 companies reported payments to CMS in program years 2021 onward. These are public disclosures, not judgments. The latest:
- AstraZeneca Pharmaceuticals LPProgram year20251 payment
- NXSTAGE MEDICAL, INC.Program year20241 payment
- Outset Medical IncProgram year20241 payment
Payment records matched to this physician's NPI in CMS Open Payments, program years 2021 onward.
Medicare prescribing footprint (2024)
The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.
Cardiovascular
54.3%Loop diuretic12.7%Torsemide61%Furosemide39%Part D<11 patientsCalcium channel blocker12.3%Amlodipine Besylate49%Nifedipine Er31%Amlodipine-Valsartan20%Part D<11 patients+ 6 more classes in this area
Metabolism & gastrointestinal
32.4%SGLT2 inhibitor17.7%Farxiga68%Jardiance32%Part D<11 patientsVitamin D3 Analog5.6%Calcitriol100%Part D<11 patients+ 2 more classes in this area
Sensory organs
4.4%Aminoglycoside Antibacterial4.4%Gentamicin Sulfate100%Part D<11 patients
Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.
Publications
Matched to this physician's OpenAlex author record; most-cited works shown first.
- Discontinuation of continuous kidney replacement therapy in patients with acute kidney injury: A pilot study
Journal of Critical Care
2026 - A retrospective cohort study on the bidirectional association between depression and chronic kidney disease
Frontiers in Nephrology
2026
Similar KOLs
Other experts from the same institution or the same specialty.
Giuseppe Remuzzi
Mario Negri Institute for Pharmacological Research
Marcello Tonelli
University of Calgary
Johan Ärnlöv
Dalarna University
Juan Jesús Carrero
Danderyds sjukhus
A basic profile from our physician directory: identity and practice contact from the federal NPPES registry, research from OpenAlex, trials from ClinicalTrials.gov, payments from CMS Open Payments — shown itemized where we have matched records, as a count where we only have a total. This person hasn't been through our full identity-adjudication pipeline yet, so funding, congress activity and public presence aren't shown. Absence of a section means “not yet looked,” never “none found.”